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TP53 belongs to a small gene family that includes, in mammals, two additional paralogs, TP63 and
TP73. The p63 and p73 proteins are structurally and functionally similar to p53 and their activity as
transcription factors is regulated by a wide repertoire of shared and unique post-translational mod-
iﬁcations and interactions with regulatory cofactors. p63 and p73 have important functions in
embryonic development and differentiation but are also involved in tumor suppression. The biology
of p63 and p73 is complex since both TP63 and TP73 genes are transcribed into a variety of different
isoforms that give rise to proteins with antagonistic properties, the TA-isoforms that act as tumor-
suppressors and DN-isoforms that behave as proto-oncogenes. The p53 family as a whole behaves as
a signaling ‘‘network’’ that integrates developmental, metabolic and stress signals to control cell
metabolism, differentiation, longevity, proliferation and death. Despite the progress of our knowl-
edge, the unresolved puzzle of complexity, redundancy and hierarchy in the p53 family continues to
represent a formidable challenge.
 2014 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
In the late 1990s the two related orthologs of TP53, TP63 and
TP73, were ﬁrst described [1,2]. The developmental functions of
TP63 (epithelial cell formation) and TP73 (a role in central nervous
system) were elucidated soon in a series of knockout-mouse exper-
iments [3–5]. At the same time, the complex gene expression strat-
egy from alternative promoters and the large number of different
functional alternative splicing isoforms described for p63 and
p73 [6], and later for p53 [7], has made the full understanding of
p53 family members functions in different tissues and physiopath-
ological contexts a difﬁcult and yet unﬁnished task. The work from
different research groups led to deﬁne the role of TA-p73 and
TAp63 in DNA damage response (DDR) and cancer cells chemiosen-
sitivity in the early 2000s [8,9] but their contribution to tumor sup-
pression was established only later through the analysis of p73 and
p63 heterozygous mutation in mice [10] and the generation of
mice selectively lacking TAp73 or TA63 isoforms [11,12]. The rep-ertoire of functions, pathways and genes regulated by p53, p63 and
p73 has progressively widened well beyond cell fate, tumor
suppression and development. p53-family members have been so
far involved in reproduction, genomic repair, ﬁdelity and recombi-
nation, metabolic processes, longevity, stem cells biology and
changes in epigenetic marks. The complexity of p53 family
expression and our incomplete understanding of the extent of
functional redundancy and operational hierarchy in different phys-
iological and pathological conditions continues to fuel the research
efforts but has, at the same time, limited a rapid translation of
knowledge into the clinical management of cancer patients. Here
we review the current evidence on p73 and p63 and their role in
cancer tumor suppression and development with a special focus
on the role of TA-p63/p73 in chemioresistance and DNp73/p63 as
oncogenes.
2. Molecular structure of p63/p73
The p63 and p73 proteins share with p53 a similar domain
organization. Full length p63/p73 (TA-p63/TAp73) contain a N-ter-
minal transactivation domain (TAD), followed by a proline-rich
sequence (PR), a central DNA-binding domain (DBD) and a C-termi-
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of active tetramers (Fig. 1). The high sequence homology (>70% of
sequence identity) in the DBDs [6,7] accounts for p73 and p63 abil-
ity to regulate many known p53 target genes (e.g. p21, PUMA,
NOXA, BAX and MDM2) [13], although the full repertoire of com-
mon and private target genes regulated by the different members
under different physiological and pathological conditions is still
to be determined. Oligomerization domains are much less con-
served: p73 and p63 form hetero-oligomerize between each other
but not, or to a limited extent with p53 [14,15].
3. Molecular complexity of p63/p73
A common feature of all p53 family members is that they can be
expressed in a number of different isoforms [6,7,16]. In p73, the
use of an internal promoter (P2), the alternative splicing of the ﬁrst
exons or the use of an alternative translation start site, generate
several variants with a truncated N-terminus, identiﬁed collec-
tively as DN-p73 [6,7]. DNp73 isoforms lack a functional transacti-
vation domain and acquire dominant negative, anti-apoptotic and
proproliferative functions over TA-p73 (see below). The C-termi-
nus of the alpha isoforms contains a sterile alpha motif (SAM),
and a terminal transcription inhibitory domain, not conserved in
p53 [6,7,9,17]. Additional shorter isoforms (b, c, d, and the less
investigated e, f and g), are generated by C-terminus alternative
splicing whose speciﬁc functions are still poorly characterized
[8,18,19] (Fig. 1).
Relatively little is known regarding the mechanisms responsible
for the differential expression of TA and DN isoforms in theFig. 1. The p53 family – a comdifferent tissues and physio-pathologicals conditions. TAp73 iso-
forms transcription from the P1 promoter is primarily driven by
E2F1 [20–22] but its activity can be also modulated by other fac-
tors such as C-EBPa [23], ZEB [24] and Ying Yang 1 (YY1) [25].
The regulation of the P2 promoter is much less clear [26–29]. In
preneoplastic cirrhotic livers and hepatocellular carcinomas
(HCCs) autocrine activation of epidermal growth factor receptor
(EGFR) by its ligand amphiregulin (AR) triggers c-Jun N-terminal
kinase-1 (JNK1) activity and inhibits the expression of the splicing
regulator Slu7, leading to the selective accumulation of DNp73
transcripts, namely DeltaEx2p73 [30]. Finally, the uncovering of
at least twelve p53 protein isoforms produced in normal tissues
through alternative initiation of translation, usage of alternative
promoters, and alternative splicing and their abnormal expression
in cancer cells has uncovered an additional level of complexity to
the p53 family [7,16].
4. Regulation of 73 and p63 functions
A complex network of post-translational modiﬁcations and pro-
tein–protein interactions control the levels and functions of all the
members of the p53 family in unstressed and stressed cells.
Several proteins have been reported to regulate p73 and p63
stability: (a) the NEDD4-like ubiquitin ligase Itch binds p73 and
p63 trigger their poly-ubiquitination and proteasomal degradation
[31,32]; (b) the transcriptional co-activator YAP1 (Yes-associated
protein 1), a key member of the Hippo signaling pathway, com-
petes with Itch for the PY motif of p73, thus allowing its stabiliza-
tion [33]; (c) mouse double minute 2 (MDM2) protein, the main E3plex expression strategy.
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feres with p300/CBP acetylation of p73 and blocks of p73 transcrip-
tional activities without triggering p73 degradation [34,35]. MDM2
does not induce p73 ubiquitination but catalyze p73 neddylation
(conjugation of NEDD8 ubiquitin-like protein) which also inhibits
p73 transcriptional activity [36]. MDM2 also binds DNp63a and
promotes its nuclear export, poly-ubiquitination by the Fbw7/
FBXW7 E3-ligase and proteasomal degradation in cells exposed
to UV irradiation or adriamycin and upon keratinocyte differentia-
tion [37]; (d) F-box protein FBXO45 binds to and promotes the
ubiquitination/degradation of both TA- and DN-p73 isoforms
[38]; (e) the U-box-type E3/E4 ubiquitin ligase UFD2a interacts
with the SAM domain of TA-p73a, and promotes its ubiquitina-
tion-independent proteasomal [39]; (f) NEDL2, a NEDD4-related
protein binds and increases p73 stability [40]; (g) the NAD(P)H
quinone oxidoreductase 1 NQO1 binds to p73 and prevents its
ubiquitin-independent degradation by the 20S proteasome [41];
(h) the peptidyl-prolyl isomerase Pin1 directly binds to and stabi-
lizes TAp63a and DNp63a by inhibiting the E3 ligase WWP1 and
proteasomal degradation [42,43]. The spectrum of functional inter-
actions between these regulators and the different p63/p73 iso-
forms has not been fully characterized. However, some factors,
such as c-Jun and the p53-induced RING-H2 E3 ligase Pirh2 have
been shown to regulate differentially the protein levels of TA-p73
and DN-p73 isoforms [44–46]. Pirh2 also physically interacts with
DNp63 that is targeted for polyubiquitination and subsequent pro-
teasomal degradation [47]. Association with ASPP (Ankirin repeats,
SH3 domain, proline-rich protein) proteins does not induce post-
translational modiﬁcations but affects p73 as well as p53 and
p63 functions: ASPP1/2 stimulate p73 and p63 transcriptional
activity, while iASPP inhibits p73 activation and p73-mediated
apoptosis [48–50].
5. p63, a developmental transcription factor
The main proof for a p63 role in human organ development is
that dominantly inherited mutations in the p63 gene are found
in a number of human ectodermal dysplasias, including ectrodac-
tyly ectodermal dysplasia-cleft lip/palate syndrome (EEC), limb-
mammary syndrome (LMS), ankyloblepharon ectodermal dyspla-
sia clefting (AEC) and non-syndromic split-hand/split-foot malfor-
mation (SHFM) [51]. These syndromes affect the development of
several organs deriving either directly from the ectoderm or from
the interaction between developing ectoderm and mesoderm
[52]. Speciﬁc genotype-phenotype correlations exist. Thus, muta-
tions causing the EEC syndrome are not found in AEC, LMS or SHFM
[53]. Moreover, the majority of mutations found in EEC syndrome
are missense mutations generating amino acid substitutions in res-
idues predicted to contact DNA [51]. Since the DNA binding
domain is present in all p63 isoforms, all isoforms of p63 are
affected by these mutations. Whether p63 DNA-binding mutants
act as dominant-negative molecules remains, however, to be deter-
mined. Mutations in exon 13 and exon 14, affecting only the alpha
isoforms of p63, are almost exclusively associated with AEC
[51,54].
Mice lacking p63 die soon after birth with several developmen-
tal defects, particularly in limb and skin development [3,4] (Fig. 2).
Defects in limb morphogenesis in p63 null mice were evident as
early as E9.5. In wild type mice, during this interval, p63 is
expressed in the surface ectoderm as well as in the ectoderm cov-
ering the limb buds and branchial arches.
The main functions of p63 is to maintain the proliferative
potential of epidermal progenitor cells [55]. Indeed, in p63 null
mice the proliferative compartment of the skin is progressively
depleted of cells and this is directly reﬂected in a severe hypoplasiaof the neonatal tissue [4]. p63 null mice activate a program of cel-
lular senescence that leads to accelerated aging [56] (Fig. 2). In par-
ticular, TA-p63 prevents premature tissue aging and maintains
dermal and epidermal precursors [57] whereas DNp63 is required
for the initial commitment of keratinocyte progenitors towards dif-
ferentiation [58]. In addition to maintain progenitor cell prolifera-
tion, p63 also impacts on epidermal stratiﬁcation and keratinocyte
differentiation. Although still a matter of debate [59,60], TAp63
isoforms, the ﬁrst p63 isoforms expressed during epidermal devel-
opment, are required for the commitment to stratiﬁcation while
they inhibit terminal differentiation [61]. After commitment to
stratiﬁcation has occurred, DNp63 isoforms induce the expression
of genes that are required for later stages of epidermal morphogen-
esis [62] but for differentiation to proceed DNp63 needs to be sub-
sequently eliminated [63,64]. The depletion of DNp63 occurs
mainly via proteasome-mediated degradation [31,32], which in
turn is controlled by several proteins some of which are transcrip-
tional targets of DNp63 [65–67]. In addition, the expression of a
p63-speciﬁc microRNA (miR203) is also important to induce p63
downregulation during terminal differentiation [68].
p63 regulates transcription by binding to p63-response ele-
ments whose repertoire is largely overlapping with p53 elements.
Indeed, many of the p53 responsive elements involved in DNA
damage-induced cell cycle arrest or apoptosis are constitutively
occupied by DNp63 in proliferating keratinocytes ([69,70] and AC
unpublished results). DNp63 controls distinct transcriptional net-
works depending on the state of maturation of keratinocyte pre-
cursors, which in turn is dependent on a variety of extracellular
stimuli. In proliferating keratinocytes of the basal layers DNp63
controls the expression of basal layer keratins (K5, K14) and of mol-
ecules required for the formation of the epidermal barrier, such as
Alox12 [71] and inhibit proliferation-induced activation of cell
cycle arrest genes by competing with p53 for the same responsive
elements. In response to differentiation stimuli, DNp63 detaches
from the promoter of cell cycle arrest genes (e.g. 14-3-3 sigma
and p21waf1), activates genes required for cell cycle exit (IKKa
and IRF6) and re-organizes the transcription of adhesion molecules
to allow keratinocytes to leave the basal layer and stratify. Thus,
differences in temporal expression, isoform combination, biochem-
ical properties and transcription activity of p63 protein(s) can have
a profound impact on the set of genes transcribed, at a given time
in a given cell.
A combination of isoform-speciﬁc siRNA-mediated downregu-
lation in primary keratinocytes and in vivo, coupled to analysis
of knock-out and disease speciﬁc knock-in mice, has allowed to
determine the key target genes required for epidermal morpho-
genesis that are involved in pathogenesis of p63-linked ectodemal
dysplasias [62,65,72,73]. These studies showed that the protein
kinase IKKa is a transcriptional target of DNp63 and, indeed,
DNp63 mutants found in ED are unable to activate the IKKa
expression. IKKa is a component of the IkB kinase complex and
is required for correct epidermal development and epithelial-mes-
enchymal interaction during development. Although NFkB regu-
lates DNp63 [74], IKKa kinase activity is not required for its
function in development [75]. IKKa null mice display defects in
epidermal, limb and craniofacial development that are fully
reverted after the re-expression of IKKa in the developing ecto-
derm [75]. Interestingly, IKKa has been recently found to be a com-
ponent of the TGFb pathway in keratinocytes [76,77] and to repress
FGF7 and FGF8 expression [75]. These observations directly link
DNp63 function to the control of developmental factors (TGFb
and FGF8) regulating epidermal, limb and craniofacial
development.
Similarly, IRF6, another DNp63 target gene, is involved in both
epidermal development and limb/craniofacial development
[65,78]. The underlying mechanism relates to the ability of IRF6
Fig. 2. TP63 and TP73 global and isoform selective knock-out mice. (See above-mentioned reference for further information.)
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required at the onset of terminal differentiation to allow protea-
some-dependent degradation of DNp63. Mutations of IRF6 cause
syndromes characterized by cleft-lip palate and other develop-
mental abnormalities, and IRF6 knock-in mice carrying the same
mutation found in patients display a hyperproliferative epidermis
that is unable to terminally differentiate [78]. Finally, members
of the BMP/TGFb and FGF families are to be considered as impor-
tant soluble mediators of this complex regulatory network [79].
6. TP73 and TP63 as tumor supressors: lessons from animal
models
The role of TAp73 and TAp63 as tumor suppressor genes was
initially challenged by two orders of evidence. First, no TP73 and
TP63 gene deletions were associated to cancer [1,80] and only a
very low percentage of human tumors (less than 1%) carry p73
or p63 mutations [81,82]. Second, the phenotype of p73/ mice
lacking all p73 isoforms (DBD exons deletion) did not support a
role in cancer (Fig. 2). p73-null mice die at 4–6 weeks of age [5]
and display neurological (hydrocephalus), reproductive, phero-
monal, inﬂammatory and behavioral defects. These observations
prevailed over the results from in vitro studies (i.e. TAp73 ability
to trigger cell cycle arrest, cellular senescence and apoptosis upon
DNA damage by promoting the transcription of many p53 target
genes [83]; the potentiation of oncogenic RasV12 in the transfor-
mation of p53/ mouse embryonic ﬁbroblasts after TAp73
knockdown [84] and the ex vivo studies in onco-hematologic
patients (i.e. P1 promoter hypermethylated and reduced TA-p73
expression in lymphoblastic leukemias and Burkitt’s lymphomas
[85,86]. The evidence to establish the role of TAp73 and TAp63
as part of an integrated tumor suppressor network with p53 came
from the study of p73 and p63 heterozygous mutation in mice and
from the generation of mice selectively lacking TAp73 or TA63 iso-
forms. Flores and coll showed that p73+/ and the p73+/:p53+/
mice developed a more aggressive tumor phenotype, compared to
p73+/+ and p73+/+:p53+/ animals [10]. p63+/ and p63+/
:p53+/ mice are also cancer-prone [10] but this appears to be
dependent on the genetic background, as p63+/ mice on a differ-
ent inbred strain show premature aging but no cancer [56,87]. Theanalysis of TAp63 selective conditional knockout mice [11,57]
showed that TA-p63 prevents premature tissue aging and man-
tains genomic stability in adult skin stem cells [57] and suppresses
tumorigenesis in vivo, irrespective of p53 status and independently
from p19(Arf) and p16(Ink4a) [11] (Fig. 2). Selective DNp63 loss
[88] results in developmental defects similar to those observed in
the original p63/ mice [4] (Fig. 2). Interestingly, the reduction
TAp63 protein levels, due to monoubiquitinated FANCD2 protein
deﬁciency, is responsible for the increased susceptibility to squa-
mous cell neoplasia in Fanconi anemia patients [89]. TA-p73/
mice, which express DNp73 isoforms, showed less severe hyppo-
campal dysgenesis, increased infertility and greater mortality by
septic shock in response to lipopolysaccharide (LPS) challenge
[12,90]. Notably, TAp73(/) also had a high incidence of sponta-
neous tumors, in particular lung adenocarcinomas [12] (Fig. 2). The
increased infertility in TA-p73/ mice is the result of a massive
and premature loss of immature germ cells due to disruption of
cell–cell adhesions of developing germ cells to Sertoli nurse cells,
defective maturation of the germ epithelium and arrested spermio-
genesis [91,92]. The impaired resolution of inﬂammatory
responses and the higher susceptibility to septic shock in
TAp73/ mice has been related to an altered macrophage polar-
ization with maintenance of an M1 macrophage effector pheno-
type together with the elevated production of TNF-a and IL-6
[90]. TA-p73 binds to and regulates the functions of Bub1 and
BubR1 in the Spindle Assembly Checkpoint (SAC) [93]. These
results, together with previous observations that implicated
TAp73 in the control of mitosis [94,95] and aneuploidy [96], clearly
assign to TAp73s a crucial role in preventing genomic instability in
multiple tissues with a speciﬁc role for TAp63s in stratiﬁed epithe-
lia. TAp73 have been also show to limit of c-Myc-driven lympho-
magenesis in vivo [97,98]. Altogether, these results not only
proved the involvement of TA-p73 and TAp63 in tumor suppres-
sion but also suggested a role of DNp73 in oncogenesis and the
importance of a proper balance between TA- and DN-p73 (and
p63) isoforms to maintain genomic integrity in proliferating cells
(see below).
Recently, global genomic expression proﬁling (RNA-Seq) and
chromatin immunoprecipitation (ChIP-Seq) experiments have
identiﬁed revealed an extensive p53-regulated autophagy program
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dent apoptosis and suppression of cell transformation but not in
cell cycle arrest [99]. Notably, the majority of the identiﬁed genes
are also by TAp63 and TAp73, suggesting that, similar to their col-
laborative induction of proapoptotic genes [100], the entire p53
family cooperates in controlling cellular homeostasis and tumor
suppression by promoting autophagy.
7. TP73, TP63 and TP53 in normal and cancer cells metabolism
The complexity of the networks engaged by the p53 family pro-
teins/isoforms to execute their physiological functions and how
they are recruited for tumorigenesis and tumor suppression is fur-
ther underlined by the emerging role of p53 and the p53 family
members in normal and cancer cells metabolism. p53 has been
reported to control several metabolic pathways, including glucose
metabolism [repression of insulin receptor (INSR) and the GLUT1
and GLUT4 glucose transporters; activation of TIGAR (TP53-
induced glycolysis and apoptosis regulator) and HK II (hexokinase
II); degradation of PGM (phosphoglycerate mutase]; the tricarbox-
ylic acid (TCA) cycle [induction of GLS2 (glutaminase 2)]; fatty acid
oxidation [activation of GAMT (guanidinoacetate aminotransfer-
ase)]; mitochondrial respiration [induction of AIF (apoptosis induc-
ing factor) and SCO2 (synthesis of cytochrome oxidase 2)] [101].
TAp63 accumulates in response to metabolic stress and activates
transcription of the two key metabolic regulators, Sirt1 and
AMPKa2, resulting in increased fatty acid synthesis and decreased
fatty acid oxidation and lowers blood glucose levels in response to
metformin [102]. TAp63/ mice, in addition to show premature
aging [57] develop obesity, insulin resistance, and glucose intoler-
ance and restoration of Sirt1 or AMPKa2 in TAp63/ mice res-
cued the metabolic defects [102]. TAp73a also regulates liver
lipid metabolism in response to nutrient deprivation by direct tar-
geting of the ATG5 gene whose product, autophagy-related protein
5, is required for autophagosome formation and triglyceride hydro-
lysis into fatty acids (macrolipophagy) [103].
Cancer cells rewire cellular metabolism to satisfy their
increased demand of bioenergy, macromolecular biosynthesis
and redox maintenance. The metabolic program of these cells is
marked by an increased uptake of glucose and glutamine to sup-
port cell growth. Most imported glucose is metabolized to lactate
through aerobic glycolysis or fueled to the oxidative pentose phos-
phate pathway (PPP) whereas glutamine serves both as a nitrogen
source for the biosynthesis of nucleotides and various non-essen-
tial amino acids and as an important carbon source for the replen-
ishment of TCA cycle intermediates [104]. TAp73, but not p53 or
p63, drives the transcription of glucose-6-phosphate dehydroge-
nase (G6PD) [105], the rate-limiting enzyme for the oxidative pen-
tose phosphate pathway (PPP) that controls the production of
NADPH and ribose needed for the synthesis of macromolecules
and detoxication of reactive oxygen species (ROS). Interestingly,
DNp73 and mtp53 do not inhibit G6PD activation by TAp73, sug-
gesting that this mechanism might be operative in proliferating
and tumor cells even in the presence of mtp53 or elevated
DNp73 levels [105]. TAp73 also targets Cox4i1, a subunit of cyto-
chrome c oxidase in the mitochondrial oxidative phosphorylation
chain that promotes oxygen consumption and prevents ROS accu-
mulation and senescence [106]. Although p53 can directly bind to
and inhibit G6PD [107], p53 also activates the transcription of
TIGAR (tp53-induced glycolysis and apoptosis regulator)
[108,109] that degrades fructose-2,6-bisphosphate to limit phos-
phofructokinase activity and promotes a sustained diversion of
glycolytic intermediates to the PPP. Glutaminase type 2 (GLS2)
transcription is activated by TAp73 [110,111], TAp63 [112] and
p53 [113,114] in normal and cancer cells. In addition to increaseATP production and oxygen consumption, the glutamate produced
by GLS2 also regulates the cellular redox balance, by supporting
the formation of glutathione (GSH) and NADPH, and affects serine
bio-synthesis, by activating the transcription factor ATF4. Serine is
a precursor for nucleotides, amino acids and lipids and an allosteric
activator of the pyruvate kinase M2 isoform (PKM2) predomi-
nantly expressed in cancer cells, thus sustaining aerobic glycolysis
and conversion of pyruvate into lactate and cancer cells prolifera-
tion [111,115]. The positive effect of TAp73 on the serine biosyn-
thesis and PKM2 activity synergizes with G6PD induction and
PPP activation [105]. NADPH production is a rate-limiting step in
cell proliferation and NADPH production is tightly controlled by
oncogenes, such as K-Ras [116] and tumor suppressors [105,117].
Indeed, TAp73 and G6PD have been shown to supports the prolif-
eration of human and mouse tumor cells [105] but restoration of
cell growth in cells lacking TAp73 by G6PD is not complete and cell
type dependent [105,118], suggesting that other TAp73 targets
might contribute to its proliferative function [119]. TAp63 has also
been found to activate cell cycle genes and promote cell prolifera-
tion in speciﬁc cell contexts [119–121]. The role of TAp73 (and
TA63) in cell proliferation is in conﬂict with the increased tumor
formation observed in TAp73- (and TAp63-) deﬁcient mice and
their tumor suppressor activity. Although there is no positive evi-
dence, a possible explanation is that any proliferative defects pres-
ent in these mice is overrun by the extensive genomic instability
and the accumulation of oncogenic mutations associated with
the early loss of TAp73 and TAp63.
8. p73 and chemiosensitivity
In response to DNA damage and chemiotherapeutic drugs sev-
eral events converge to build up the TAp73 apoptotic response
[122]. As part of the DNA damage response (DDR), E2F1 is acety-
lated by PCAF [123,124], phosphorylated by the Chk1/2 kinases
[125] and directed to the P1 promoter to induce TA-p73 expression
[123], whereas E2F1 deacetylation by Sirt1 inhibit of TA-p73 tran-
scription [126]. Similarly, E2F1 methylation by Set9 and its
demethylation by LSD1 enzymes regulate E2F1-dependent activa-
tion of TA-p73 expression and induction of apoptosis [127]. Multi-
ple kinases activated in the DDR phosphorylate TAp73 proteins
leading to its stabilization and accumulation (Fig. 3): (a) the non-
receptor tyrosine kinase c-Abl [TA-andDN-p73safterc-radiation-
orcisplatintreatment] [128–130]; (b) ATM (Ataxia Telangiectasia
Mutated) serine-protein kinase [after cisplatin treatment] [130];
(c) the downstream effector of ATM Chk2 [131]; (d) protein kinase
Cd (PKCd) [TA-p73b at Ser289 [132]]; JNKs [TA-p73 after cisplatin
treatment] [133]; p38 phosphorylation of threonine residues criti-
cal for p73 activation by c-Abl [134]. ATM also modulates p73 lev-
els in response to cisplatin by activating cAbl [135] and by
phosphorylating IKK-a that accumulates in the nucleus and pro-
motes p73 stabilization [136,137]. Finally, in response to DNA
damage Itch levels are downregulated by yet unknown mecha-
nisms to relieve TAp73s from Itch-induced degradation and to
allow TAp73 accumulation [2]. Although TAp73 proteins accumu-
lation is expected to translate into a global increase of target genes
expression, TAp73 apoptotic capacity is fully activated by p300-
mediated acetylation that increases interaction with the YAP1
transcriptional co-factor [138–140] and directs TAp73/YAP com-
plexes to the promoters of apoptotic target genes [138,141]. Nota-
bly, both TAp73 conformational changes catalyzed by Pin prolyl
isomerase [142] and c-abl-mediated tyrosine phosphorylations
are required for TAp73 acetylation by p300 [141,142]. It is impor-
tant to consider that DN-p73 is, or can be, targeted by many of the
phosphorylations associated with the DDR response, as well as by
p300-mediated acetylation, resulting in the accumulation of DN-
Fig. 3. p73 stabilization and activation in response to DNA genotoxic insults.
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levels of TA-p73 and DN-p73 isoforms play an important role in
the maintenance of TAp73 apoptotic and tumor suppressor activi-
ties. The p73-induced ring-ﬁnger domain ubiquitin ligase PIRH2
preferentially degrades DN-p73, thus releasing TA-p73 and trigger-
ing apoptosis following DNA damage [46]. c-Jun triggers the pro-
teasome-mediated ubiquitin-independent degradation of DN-p73
in response to DNA damage by inducing the expression of the
non-classical polyamine-induced antizyme (Az) [45].
The activation and contribute of TAp63 in the DDR is much less
clear. However, a strong link between DN-p63 and chemiosensitiv-
ity has been established in head and neck squamous cell carcino-
mas (HNSCC) where DN-p63 expression in vivo correlates with
chemo- and radio-resistance and the experimental knockdown of
endogenous p63 in HNSCC cells by RNA interference resulted in
induction of TA-p73-dependent apoptosis [143]. Similarly, in cell
lines derived from triple negative breast cancers (TNBC, lacking
estrogen and progesterone receptors and with Her2 ampliﬁcation),
the activation of the cAbl/TA-p73 axis and apoptosis in response to
cisplatin requires the release of TA-p73 from DNp63 [144] and DN-
p63 levels are crucial for TNBC chemiosensitivity.
Despite the bulk of evidence that supports the role of TAp73 in
chemiosensitivity in cell and animal models, less is know about
their contribute to chemio-resistance and chemiosensitivity in
human cancers. mt-p53s bind and inhibit TAp73 and TAp63 as part
of their GOF activity (‘‘gain of function’’).
The presence of a polymorphic site at codon 72 of wt- and mt-
p53 that encodes either an arginine (72R) or a proline (72P) [145–
147] impacts on p73-dependent chemotherapeutic responses of
cancers bearing mutp53. wt-p53 72R induces apoptosis much bet-
ter than the 72P variant [147] whereas mut-p53 72R confers higher
chemoresistance to cancer cells as compared with mut-p53 72P
[145,146,148].
9. DN-p73s as a proto-oncogene
The oncogenic role of N-terminally truncated DN-p73 isoforms
is supported by many in vitro and in vivo evidence. DN-p73 over-
expression in ﬁbroblasts increases their colony formation capacity
[149] and cooperates with RAS, cMyc and E1A in promoting trans-
formation and tumorigenicity [84,150]. Liver DN-p73 (in particular
Dex2/3-p73a) transgenic mice display increased hepatocytes
proliferation and develop both adenomas and hepatocellular carci-
nomas (HCC) [151] (Fig. 2). Several mechanisms contribute to the
oncogenic potential of DN-p73 isoforms. DN-p73s exert a
dominant negative effect on both p53 and TA-p73 and TA-p63,by competing for binding to the same target promoters as DN-tet-
ramers and by oligomerizing with them to form transcriptionally
ineffective heterocomplexes [143,152]. In addition, DN-p73s pro-
mote RB hyper-phosphorylation by cyclin E-Cdk2 and cyclin D-
Cdk4/6 kinases, resulting in E2F deregulation and cell cycle pro-
gression [151,153,154]. Finally, some C-terminal variants of DN-
p73 can up-regulate anti-apoptotic genes independently of p53
[155–157].
More importantly, DN-p73 is overexpressed in several tumors,
among them breast [152], ovary [158,159], prostate cancers
[160], melanoma [161], neuroblastoma [162] and hepatocellular
carcinoma [163,164] and in most cases, DN-p73 expression is asso-
ciated with therapy failure, chemoresistance, metastasis and vas-
cular invasion [165]. In melanoma xenografts DNp73 expression
is associated with upregulation of Slug, downregulation of the
actin binding protein EPLIN, activation of the IGF1R-AKT/STAT3
pathway, loss of E-cadherin and a higher ability to invade and
metastasize [166].
DN-p73 levels and DN- to TA-p73 ratio determine the net effect
of p73 and seem to predict the effectiveness of chemotherapy
[8,122,144]. Several signaling and/or oncogenic pathways impact
TA- and/or DN-p73 levels by affecting transcription or protein sta-
bility. H-RasV12 overexpression in primary ﬁbroblasts down-regu-
lates TA-p73 and increases both DN-p73 expression and anchorage
independent cell growth [167]. Importantly, both p53 and TA-p73
bind the internal P2 promoter of TP73, activate the transcription of
P2 DN-p73 isoforms [26,28,29] and create a negative feedback loop
between DN-p73 and p53/TA-p73 that may self-restrict their tran-
scriptional activities.
10. DNp63 links organ development and tumorigenesis in skin
cancer
DNp63a is the major p63 isoform expressed in stratiﬁed squa-
mous epithelium and in squamous cell carcinomas (SCC)
[168,169]. DNp63 contribution to skin tumorigenesis well illus-
trates the current view of cancer as the result of complex interac-
tions between transformed cells and multiple cell types with the
tumor microenvironment and the impact of genes involved in
organ development. In this perspective, DNp63 oncogenic
potential is related not only to a direct competition with p53,
TAp63 and TAp73 on the same p53 Responsive Elements and the
consequent inhibition of p53/p73 mediated activation [70] and to
its interactions with the other p53 family members and their
modulators (i.e. ASPP1/2, HIPK2, mdm2, Pin1, Pirh2
[37,42,43,47,48,170,171] but also to its ability to control transcrip-
Fig. 4. p63 upstream modulators and effectors.
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ways, such as IRF6, IKKa and FGFR2 [172–174] (Fig. 4). IKKa and
IRF6 functions in skin and organ development has been described
above. We found that both IKKa and IRF6 are strongly downregu-
lated in SCCs, and that their expression is correlated negatively
with cancer differentiation [172–174]. IKKa acts in epithelial cells
as a component of the anti-proliferative branch of the TGFbeta sig-
naling pathway, that is frequently inactivated in cancers
[76,172,175] but has also another function as repressor of FGFs
expression [75,176,177]. IRF6 acts on a partially different pathway,
being a mediator of Notch1 anti-cancer activity [178], but also a
repressor of cMyc and FGF pathways. Interestingly, recent data
indicate in the Receptor 2 for the Fibroblast growth factors (FGFR2)
a critical mediator of DNp63 oncogenic functions in SCCs [174],
whose inhibition favors tumor regression the same way DNp63
depletion does. FGFR2 is the receptor for FGF7, 8 that are speciﬁ-
cally downregulated by IKKa, and IRF6 ([75,177] and AC personal
communication). Altogether these informations suggest a model
in which DNp63 acts as a regulator of p53 tumor suppressive func-
tions in a cell autonomous way, and as a mediator of activation of
FGF signaling pathway in a paracrine way.
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